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ABSTRACT
The coxsackievirus and adenovirus receptor (CAR) is a cell contact protein with an important role in virus uptake. Its extracellu-
lar immunoglobulin domains mediate the binding to coxsackievirus and adenovirus as well as homophilic and heterophilic in-
teractions between cells. The cytoplasmic tail links CAR to the cytoskeleton and intracellular signaling cascades. In the heart,
CAR is crucial for embryonic development, electrophysiology, and coxsackievirus B infection. Noncardiac functions are less well
understood, in part due to the lack of suitable animal models. Here, we generated a transgenic mouse that rescued the otherwise
embryonic-lethal CAR knockout (KO) phenotype by expressing chicken CAR exclusively in the heart. Using this rescue model,
we addressed interspecies differences in coxsackievirus uptake and noncardiac functions of CAR. Survival of the noncardiac
CAR KO (ncKO)mouse indicates an essential role for CAR in the developing heart but not in other tissues. In adult animals, car-
diac activity was normal, suggesting that chicken CAR can replace the physiological functions of mouse CAR in the cardiomyo-
cyte. However, chicken CAR did not mediate virus entry in vivo, so that hearts expressing chicken instead of mouse CAR were
protected from infection andmyocarditis. Comparison of sequence homology andmodeling of the D1 domain indicate differ-
ences betweenmammalian and chicken CAR that relate to the sites important for virus binding but not those involved in ho-
modimerization. Thus, CAR-directed anticoxsackievirus therapy with only minor adverse effects in noncardiac tissue could be
further improved by selectively targeting the virus-host interaction while maintaining cardiac function.
IMPORTANCE
Coxsackievirus B3 (CVB3) is one of the most common human pathogens causing myocarditis. Its receptor, the coxsackievirus
and adenovirus receptor (CAR), not only mediates virus uptake but also relates to cytoskeletal organization and intracellular
signaling. Animals without CAR die prenatally with major cardiac malformations. In the adult heart, CAR is important for virus
entry and electrical conduction, but its nonmuscle functions are largely unknown. Here, we show that chicken CAR expression
exclusively in the heart can rescue the otherwise embryonic-lethal CAR knockout phenotype but does not support CVB3 infec-
tion of adult cardiomyocytes. Our findings have implications for the evolution of virus-host versus physiological interactions
involving CAR and could help to improve future coxsackievirus-directed therapies inhibiting virus replication while maintain-
ing CAR’s cellular functions.
Coxsackieviruses belong to the Enterovirus genus in the familyof Picornaviridae and are important human pathogens, which
cause a plethora of infectious diseases such as myocarditis, men-
ingitis, and pancreatitis (1). They are one of the most common
causes of myocarditis, with up to 33% of patients positive for
coxsackievirus group B (CVB) (2). The classification of coxsacki-
eviruses is based on the systemic versus localized pathology in the
mouse, which is the experimental model of choice to study the
CVB3 serotype (3, 4). In addition to mouse and human, other
species are also infected by CVB3, which has been reported in
diverse primate species with myocarditis (5–7). Infections with
other CVBs have been reported in primates and dogs (8, 9). Infec-
tions of the pig have been attributed to the swine vesicular disease
(SVD) virus—an adaptation of the human CVB5 to the swine
(10).
The coxsackievirus andadenovirus receptor (CAR)was identified
in1997(11,12)andbindsgroupBcoxsackievirusesandadenoviruses
of the subgenera A andC to F, as well as the SVDvirus (12–14). CAR
is crucial for CVB3 uptake as documented by protection from infec-
tion of heart or pancreas in the respective tissue-specific knockouts
(3, 4). Virus attachment ismediated by binding of CAR’sN-terminal
immunoglobulin (Ig) domain to the canyon of the virus, where the
viral capsid proteins VP1 to -3 interact with CAR (15). This interac-
tion is conserved in the family Picornaviridae (16–18). CVB3s use
the coreceptor decay accelerating factor (DAF) for cell attachment
(19), which binds adjacent to the CAR interaction sites on the
virus surface (20). DAF alone is not sufficient for virus infection
(21). It has been proposed to facilitate the presentation of virions
to CAR and contribute to systemic infections, helping the virus to
cross epithelial cell barriers (22).
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CAR is a type I transmembrane protein localized in the tight
junctions of epithelial cells and in the intercalated discs between
cardiomyocytes (23, 24). It consists of an N-terminal signal pep-
tide, two extracellular Ig domains, a transmembrane domain, and
an intracellular tail. Because of its two extracellular Ig-like do-
mains, CAR belongs to the immunoglobulin superfamily (IgSF)
(11). TheN-terminal Ig domain is important for virus binding but
also for homophilic interactions or interaction with other IgSF
proteins (15, 25–27). The cytoplasmic tail contains a PDZ-bind-
ing motif (28) that links to the cytoskeleton and intracellular sig-
naling cascades (24, 29, 30).
To analyze the role of CAR in vivo, several knockout (KO)
animals have been generated (31). Conventional CARKOanimals
die between embryonic day E11.5 and E13.5 (32–35). The em-
bryos suffer from defects in cardiac development, hemorrhage,
and edema. Their myofilaments are disorganized and less com-
pact than those of wild-type (WT) controls. To circumvent the
embryonic-lethal phenotype and analyze the function of CAR in
the adult heart, several conditional KO animals have been gener-
ated (33, 35, 36). The adult KOs revealed a role for CAR in the
electrical signal propagation between atrium and ventricle (35–
37). Together, this indicates an essential function of CAR in both
the embryonic and the adult heart. Deletion of CAR in noncardiac
tissues did not result in severe phenotypes (3, 37).
To analyze possible noncardiac functions ofCARand its role in
mediating and sustaining coxsackievirus infections, we generated
a novel animalmodel that expresses CAR exclusively in cardiomy-
ocytes but not in other cells. With Gallus gallus CAR (chCAR)
under the control of the heart-specific MLC-2 promoter, we were
able to rescue the embryonic-lethal phenotype of the conventional
CAR KO. CVB3 infection studies of the noncardiac CAR KO
(ncKO) mouse demonstrate the protection from pathology
throughout the body, including the heart, where mouse CAR
(mCAR) is replaced with chCAR. Sequence alignment and mod-
eling of the protein structure indicated crucial differences inCAR-
CVB3 interaction between species. The respective amino acids
were less well conserved than were the amino acids involved in
homodimerization and cluster differentiallywithin the Ig domain.
MATERIALS AND METHODS
Animal procedures. All experiments involving animals were carried out
following the Guide for the Care and Use of Laboratory Animals of the
German Animal Welfare Act, and protocols were approved by the Com-
mittee on the Ethics of Animal Experiments of Berlin state authorities and
the regional board of Tübingen.
In brief, we generated a transgenic mouse (TG) that expresses the
full-length CAR protein fromGallus gallus, including all annotated exons
(chCAR), under the control of the heart-specific MLC-2 promoter, in
addition to thewild-typemouseCAR.Animalswith high expression levels
of chCAR as determined by TaqMan analysis died early postnatally, while
lower levels were compatible with life. These animals were mated with
heterozygous CAR knockout mice (38) for two generations to obtain res-
cue animals, which are homozygously deficient for mouse CAR and ex-
press chicken CAR only in the cardiac ventricle. The colony was main-
tained by breeding animals with and without the transgene to ensure
heterozygosity for the transgene and to reduce potential side effects from
integration of the transgene.
For echocardiography or electrocardiogram (ECG) analysis, mice
were anesthetized with 1.5% isoflurane. For echocardiography, M and B
modes were measured with the Vevo 2100 system (Visual Sonics) and the
MS400 transducer. Data acquisition and analysis with the Vevo 2100 soft-
ware, including the trace ejection fraction (EF) (%), have been described
previously (39). ECG standard intervals were measured in six-limb leads.
The ECG was recorded with the PL3508 PowerLab 8/35 data acquisition
system (AD Instruments). Data analysis was performedwith the LabChart
7.3 software (AD Instruments). For body composition analysis by mag-
netic resonance (MR) technology, we used the LF90II body composition
analyzer (Bruker). The Evans blue (EB) extravasation assay was per-
formedby injecting 4ml of 2% (wt/vol) EBdye solution/kg of bodyweight
(BW) intravenously. Two hours later, the animals were sacrificed. The
brains and kidneys were dissected and photographed. Ten-milligram sec-
tions of the organs were then homogenized in phosphate-buffered saline
(PBS), mixed with the same volumes of 60% trichloroacetic acid, and
centrifuged (10,000 rpm, 20 min). Absorbance of the supernatants was
measured at 620 nm.
Electron microscopy. Mice were killed by cervical dislocation and
perfused with 4% paraformaldehyde (PFA) in phosphate buffer. Left ven-
tricular tissuewas postfixedwith 2.5%glutaraldehyde in phosphate buffer
overnight. Tissues were washed with cacodylate buffer, treated with 1%
osmium tetroxide (pH 2.5) for 2 h, and dehydrated in a graded ethanol
series. Tissues were embedded in Epon resin, cut in 70-nm sections, and
contrasted with uranyl and lead citrate. Pictures were taken with a Zeiss
910 electron microscope and a charge-coupled device (CCD) camera
(Proscan).
Virus inoculation.The CVB3Nancy strain (40) was grown and prop-
agated in Vero cells. Stock virus was prepared by freezing and thawing
three times and purified by sucrose gradient centrifugation as described
previously (41). The same stock was used to infectmice by intraperitoneal
injection with 1 105 PFU or intravenously with 1 106 PFU of purified
CVB3. Animals were analyzed 4 or 10 days postinjection (dpi) with virus.
Cell culture.Cells were cultured in Dulbeccomodified Eagle medium
(DMEM; Lonza) supplemented with 10% fetal calf serum (FCS), 100
U/ml penicillin, and 100 g/ml streptomycin and incubated at 37°C with
5% CO2.
Transfection was performed using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions. For one cavity of a 6-well
plate, 2.6 g plasmid DNA was used. Protein expression was analyzed 48
h after transfection.
Transfected CHO cells were infected with CVB3 at a multiplicity of
infection (MOI) of 0.1 for 30 min at 37°C. Subsequently, cells were
washed twice with PBS. For RNA preparation, cells were lysed 4 h postin-
fection with 1 ml TRIzol. For plaque assay, cells with supernatant were
harvested 24 h postinfection and lysed by three cycles of freezing and
thawing.
Plaque assay. Plaque assays were carried out as described previously
(42). Briefly, HeLa cells were cultured in six-well culture plates as conflu-
ent monolayers at a density of 1 106 cells/well. After 24 h, medium was
removed and cells were overlaid with 1 ml of diluted supernatant har-
vested from infected CHO cells and then incubated at 37°C for 30 min.
After removal of the supernatant, cells were overlaid with 2 ml of agar
containing Eagle’s minimal essential medium (MEM). Three days later,
the cells were stained with 0.025% neutral red in PBS. Virus titers were
determined by counting plaques 3 h after staining. Data shown represent
the results of two independent plaque assays, each performed in duplicate.
Immunofluorescence analysis. H9C2 cells transfected with the ch-
CAR expression construct were fixed with 4% PFA in PBS and stained
according to the published protocol (43). Primary antibody was a rabbit
anti-chCAR antibody targeting the extracellular domain of chCAR (a gen-
erous gift from Fritz Rathjen [26]). As secondary antibody, we used an
anti-rabbit IgG Cy3-conjugated antibody raised in goat (Invitrogen). Im-
age acquisition was performed on a Leica SPE microscope, and Image
analysis was done in ImageJ (44).
Tissue preparation. Samples of tissues were either quick-frozen in
liquid nitrogen for the subsequent preparation of RNA or fixed for 12 h
in phosphate-buffered (pH 7.2) 4% paraformaldehyde and embedded in
paraffin for histology, immunohistology, and in situ hybridization.
Freiberg et al.
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Western blotting. Protein preparation, SDS-PAGE, and Western
blotting have been previously described (44). Primary antibodies used
against chCAR (a generous gift from Fritz Rathjen; 1:500) and glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) (mouse monoclonal; Calbi-
ochem; 1:5,000) and secondary antibody conjugated with horseradish
peroxidase (HRP;GEHealthcare Life Sciences; 1:5,000)were used accord-
ing to the manufacturer’s instructions.
Histopathology. Histological analysis was performed on deparaf-
finized 5-m-thick tissue sections that were stained with Masson’s
trichrome or hematoxylin and eosin (H&E) to assess cellular injury and
inflammation (45). Immunohistochemistry using the CVB3-specific VP1
antibody (1:400) provided by Mediagnost (Reutlingen, Germany) was
used to follow CVB3 replication. Subsequently, the sections were pro-
cessed with the MaxHomo Mouse on Mouse Polymer HRP detection kit
(MaxVision, Washington, USA) followed by HistoGreen substrate (Li-
naris, Dossenheim, Germany). The tissue sections were counterstained
with hematoxylin.We evaluated cellular damage comprising cell necrosis,
inflammation, and scarring as published previously (46), using a Zeiss
Axioskop 40microscope, with the following grading system: 0, no cellular
damage and/or inflammatory infiltrates; 1, small foci of tissue damage
and/or inflammatory cells; 2, larger foci of damage and/or100 inflam-
matory cells; 3, larger foci with an area of 10% of a cross-section in-
volved; 4, 10 to 30% of a cross-section involved; 5, up to 100% of a
cross-section involved.
CVB3 RNA in situ hybridization. For localization and quantification
of CVB3 RNA in paraffinized tissue sections, we used radioactive in situ
hybridization. At the indicated time points, tissue samples were fixed in
4% paraformaldehyde-0.1 mol/liter sodium phosphate buffer (pH 7.2)
and embedded in paraffin for detection of viral RNA with a 35S-labeled
enterovirus-specific RNA probe as previously described (41, 45). For
quantification of CVB3 RNA in high-power fields (200), we used the
following scoring system: 0, no positive cells; 1, a few small foci with
positive cells; 2, several foci with100 positive cells; 3,10%of the tissue
containing positive cells; 4, 10 to 30% of the tissue containing positive
cells; 5, up to 100% of the tissue containing positive cells. The same score
was used for detection of VP1-positive cells using a Zeiss Axioskop 40
microscope, also reflecting virus replication at the cellular level.
Expression analysis. RNA from the indicated tissues was amplified
with specific TaqMan probes (sequence available on request). The gene
expression assays for RANTES and beta interferon 1 (IFN-1) as well as
the 18S RNA as a housekeeping gene were purchased from Applied Bio-
systems (Foster City, CA). Data acquisition and analysis have been previ-
ously described (47).
Multiplex bead immunoassay. To measure the serum concentration
of RANTES, we used the BioPlex Pro mouse cytokine assay (Bio-Rad)
according to themanufacturer’s instructions. The fluorescence signal was
detected using the Luminex 200 system (Millipore). Concentration was
determined using a standard curve. All samples were run in triplicate.
Coxsackievirus B3 IgG serum ELISA. To determine the concentra-
tion of CVB3-specific antibodies, the Serion enzyme-linked immunosor-
bent assay (ELISA) classic coxsackievirus IgG kit (Virion Serion) was used
according to the manufacturer’s instructions. Serum samples were ini-
tially diluted 1:200. The secondary antibody was replaced by an alkaline
phosphatase-coupled anti-mouse IgG antibody (Invitrogen). The signal
at 450 nmwasmeasured with the F200 Promicroplate reader (Tecan). All
samples were run in triplicate.
Statistical analysis. For statistical analysis, GraphPad Prism software
5.0 (San Diego, CA) was used. Results are expressed as means standard
errors of themeans (SEM). To compare two groups, the Student t test was
performed. Analysis of more than 2 groups was performed by one-way
analysis of variance (ANOVA). Asterisks in the figures indicate statisti-
cally significant differences (*, P 0.05; **, P 0.01; ***, P 0.001).
Homology modeling of Gallus gallus CAR D1 domain. The three-
dimensional structure of the CAR D1 domain amino acids (aa) 19 to 144
(UniProtKB accession number P78310) fromHomo sapiens (PDB identi-
fier [ID] 1RSF chain A) was used as the template for homology modeling.
The homology modeling of the Gallus gallus CXADR D1 domain amino
acids 20 to 139 (UniProtKB accession number F1NSL7) was performed
using the ESyPred3D homology modeling program (48). The resulting
three-dimensional structure was analyzed and compared using the Dis-
covery Studio Visualizer 3.1 (Accelrys).
RESULTS
Heart-specific expression of CAR rescues the embryonic-lethal
CAR KO phenotype. CAR is essential for embryonic develop-
ment, as knockouts die in midgestation with cardiac malforma-
tions and hemorrhage (32–34). To test if survival exclusively de-
pends on CAR expression in the heart and to potentially
circumvent the embryonic-lethal KO phenotype, we used a ge-
netic rescue approach with cardiac tissue-specific expression of
chCAR in the CAR KO mouse. We inserted the coding region of
chicken CAR into the MLC-2 expression vector and validated the
construct by restriction analysis and sequencing of the open read-
ing frame (Fig. 1A). The MLC-2 promoter restricts expression to
the heart, and its perinatal regulation matches that of CAR with
high expression in the embryo and reduced levels after birth (49).
To confirm protein expression, the rat cardiomyoblast cell line
H9C2 was transfected with the MLC-2 chCAR expression con-
struct followed by immunofluorescence staining with an anti-ch-
CAR antibody (Fig. 1B). After validation of protein expression
and proper localization of chCAR at the plasma membrane, we
used pronuclear microinjection of the linearized construct to ob-
tain transgenic (TG) animals. Founders with high expression lev-
els of the chCAR transgene died within the first weeks of age (data
not shown). Surviving transgenic animals were backcrossed to the
CAR KOmice for two generations to obtain noncardiac CAR KO
animals (ncKO), which survive and do not display an obvious
phenotype (Fig. 1C and D). To validate the ncKO model, we de-
termined CAR protein expression by Western blotting (Fig. 1E)
and CARmRNA levels by reverse transcription-quantitative PCR
(qRT-PCR) with specific primers discriminating between mouse
and chicken CAR. RNA from several tissues was isolated from
10-week-old mice, which express CAR at low levels, but it was
clearly distinct from the background signal in ncKO animals (Fig.
1F). Expression of the transgenic chCAR was restricted to the
heart of the ncKO mice (Fig. 1G), with no activity of the MLC-2
promoter in other tissues. The transgenic animals as well as the
ncKOmice developed normally. Their weight and the body com-
position of fat, free water, and muscle tissue did not differ from
those of wild-type (WT) animals (Table 1). Because of the impor-
tance of CAR in cardiac development and function, the hearts of
the ncKO mice and the parental transgenic strain underwent ad-
ditional analysis. The heart-weight-to-body-weight ratio of these
animals was normal (Fig. 1H), as was the histology of adult hearts
(Fig. 1I). There were no signs of hypertrophy, dilation, or changes
in tissue composition. The ultrastructure as determined by elec-
tron microscopy was unremarkable in the rescue animals, in con-
trast to the conventional (34) or cardiac (35) CAR KO mice. The
myofilament structure, mitochondria, and intercalated discs ap-
peared normal in all genotypes (Fig. 1J). Cardiac function, as de-
termined by echocardiography, was unchanged in TG or ncKO
animals (Table 2). The electrical activity of the heart that was
affected in the cardiac CAR KO with atrioventricular (AV) block
(35–37) was normal in both strains (Table 3). Thus, chCAR com-
pletely restores the cardiac function of mCAR in the rescue ani-
Interspecies Differences in CAR (Patho-)physiology
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mals. Furthermore, there were no obvious phenotypes observed
caused by the deletion of CAR in other tissues studied, as the
animals developed normally and had a normal body composition
and an intact blood-brain barrier (Fig. 1K to M).
TheCARncKOmouse isprotected fromCVB3 infection.The
relevance of CAR and its coreceptors for virus entry and CVB3-
associated pathology has recently been addressed using loss-of-
function mutants in heart and pancreas (3, 4). To facilitate the
FIG 1 Generation and basic characterization of the noncardiac CAR knockout mouse (ncKO). (A) The CAR expression construct contains the MLC-2 promoter,
-globin intron 2, chickenCARcDNA(chCAR), and the simian virus 40 polyadenylation sequence (SV40pA). (B) Proper expression and localizationwere validated by
immunofluorescence of chCAR(green) inH9C2 cells.Nuclei are stained inblue (4=,6-diamidino-2-phenylindole [DAPI]). Bar, 20m. (C)Breeding scheme.TheMLC
promoterdrives expressionof chCARexclusively in theheart (a).MouseCAR is expressed fromthewild-type alleles. Theheterozygousknockout contains a recombined
CAR allele with a residual lox side after excision of exon 1 (triangle; b). Homozygous CAR knockout mice with the chCAR transgene (k) are available after two
generations. (D) Pedigree of the heart-specific CAR rescue animals with the parental (P), F1, and F2 generations. Genotypes of animals (a to k) are provided below. The
transgenic mouse expresses chicken CAR (chCAR) under the control of the heart-specific MLC-2 promoter (a). These animals were mated with heterozygote CAR-
deficient mice carrying the recombined mouse CAR allele (CAR rec; b). Heterozygous offspring with (e) and without (f) the transgene were mated to obtain the
noncardiac CAR KO animals (k). (E) In transgenic animals, chicken CAR (chCAR) protein is expressed and localizes to the intercalated disc. (F) In wild-type tissues,
mouseCARmRNA is expressed at normal levels as determined byTaqMan analysis, while expression in noncardiac knockoutmice (ncKO) is at the detection limit (Fc,
fold change). (G) The chCAR transgene is exclusively expressed in the hearts of ncKO animals. (H) Heart-weight-to-body-weight ratio (HW/BW) was normal in
transgenic andncKOanimals. (I)Masson’s trichrome stainingof paraffin sections fromhearts of 10-week-oldwild-type (WT), chCAR transgenic (TG), andnoncardiac
CAR KO (ncKO) mice. There were no differences in heart morphology and tissue composition. Bar, 1 mm. (J) Ultrathin sections of hearts from 10-week-old WT,
transgenic, and ncKO mice were analyzed by electron microscopy. The left panel shows the intercalated discs; the right panel shows the myofilament structure with
mitochondria. Therewere no differences in cardiac ultrastructure. Bar, 2m. (K and L)CARWTandncKOmicewere injected intravenouslywith 2%Evans blue (EB)
dye to test the blood-brain barrier function. The brains (K) of bothWTandncKOmice showedno signs of dye leakage, as opposed toWTandncKOkidneys (L),which
stained dark blue. (M) Absorbancemeasurement of extravasated EB confirmed that ncKOmice had no increase of the dye content in the brain compared toWTmice.
TheamountofEBextracted fromthebrainsofbothWTandncKOanimalswas significantly smaller than theamountextracted fromthekidneys (P0.001).WT,n4;
ncKO, n 4. Bar, 1 cm.
Freiberg et al.
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differential analysis ofmultiple organs and to determine howCAR
influences virus spread within the organism, we infected WT and
ncKO animals intraperitoneally with the CVB3 Nancy strain. Ten
days after infection, tissues were isolated and analyzed for virus
and associated pathology, such as signs of inflammation. Of the
noncardiac tissues analyzed,we foundnecrotic lesions in histolog-
ical sections of the pancreas of WT but not ncKO animals (Fig.
2A). The area of necrosis and inflammation with infiltration of
mononuclear cells was used to assign an arbitrary score from0 (no
damage) to 5 (30 to 100% affected area). For WT pancreas, the
inflammation score was 4.70 0.48 (mean standard deviation
[SD]). Spleen, liver, kidney, and lung appeared normal in both
genotypes (score 0). In situ hybridization with a probe specific for
viral plus-strand RNA confirmed replicating virus in the exocrine
pancreas of WT but not of ncKO animals (Fig. 2B). The presence
of viral RNAwas scored from 0 (no positive cells) to 5 (30 to 100%
positive cells). In the pancreas of wild-type mice, the infection
score was 4.20 0.42 (mean SD). There was no viral RNA as a
sign of replicating virus in ncKO animals (score 0).
In a more global approach to virus infection, we analyzed the
immune response in animals exposed to CVB3. Intraperitoneal
infection of ncKO mice did not result in the induction of inflam-
mation markers. CVB3-specific IgG levels were increased from 4
through 10 days postinfection (dpi) in wild-type animals, while
ncKO animals did not produce a specific immune response. In the
serum of ncKOmice at 4 or 10 dpi, there was no induction of the
inflammation marker “regulated on activation, normal T-cell ex-
pressed and secreted” (RANTES). In contrast, WT animals had
high levels of serumRANTES in the acute phase of the infection at
4 dpi, which decreased butwere still elevated in the subacute phase
at 10 dpi (Fig. 3).
As there was no prominent immune response to virus load in
the ncKO mouse, we investigated if CVB3 infection was blocked
not only in noncardiac cells but also in cardiomyocytes of the
rescue animals. We analyzed hearts from ncKO mice in the acute
phase of infection and found that hearts expressing chCAR instead
of mCAR were protected from CVB3 infection. Comparing WT
versus ncKO hearts at 4 and 10 dpi, we found signs of infiltration,
viral CVB3 RNA, and VP1 protein only in the wild-type mice, not
in ncKO mice (Fig. 4A to D). Quantification was based on the
affected area and/or number of positive cells with infiltration
based on histology (WT, 1.30 0.48, versus ncKO, 0.0 0.0), in
situ hybridization (WT, 1.20 0.42, versus ncKO, 0.0 0.0), and
presence of capsid protein VP1 (WT, 0.8  0.42, versus ncKO,
0.0 0.0).
We also tested the expression of the cytokines RANTES, tumor
necrosis factor alpha (TNF-	), beta interferon 1 (IFN-1), inter-
leukin 6 (IL-6), and interleukin 10 (IL-10) in infected heart tissue
samples. In contrast to WT animals, there was no induction in
ncKO mice (Fig. 4E).
To determine if the route of delivery in the ncKO mouse af-
fected virus-induced cardiac pathology, we performed a second
set of infections delivering the virus intravenously to ensure that
the virus reached the heart. Viral RNA was present in wild-type
hearts (infection score, 1.25 0.50) andpancreas (infection score,
4.25  0.50). Again, there were no histological signs of infection
and no viral RNA in the hearts of infected ncKO animals (Fig. 5A).
Intravenous delivery resulted in a slight induction of CVB3-spe-
cific IgGs, but there was still a significant difference from WT
animals with replicating virus (Fig. 5B). The slight induction in
the ncKOmousemight be caused by circulating virus in the blood
and does not necessarily indicate a viral infection. Serum levels of
RANTES were increased only in WT animals (Fig. 5C). Taken
together, the protection from virus infection of noncardiac and
cardiac tissue when mouse CAR is replaced by chicken CAR indi-
cates an important role for CAR in mediating virus uptake
throughout the body and suggests a species-specific interaction of
CVB3 with its receptor.
CVB3 infection is species dependent. As chCAR restored the
physiological functions of mCAR but did not mediate CVB3 in-
fection, we investigated differences in virus uptake in a cell culture
system. Native CHO cells were not infected with the CVB3 Nancy
strain but with the PD strain, which entered cells independently of
CAR (50) and resulted in high virus titers (Fig. 6A). CHO cells,
which do not express CAR and thus cannot be infected by the
CVB3 Nancy strain (51), were transfected with mouse CAR
(mCAR) or chicken CAR (chCAR) and subsequently infected
with CVB3. Transfection of CHO cells with mouse CAR resulted
in high levels of infection and virus replication verified by a plaque
assay. Nontransfected CHO cells and cells transfected with
TABLE 2 Echocardiography of transgenic and ncKO animals
Characteristica
Value for mouse type:
WT (n 8) TG (n 5) ncKO (n 6)
BW (g) 21.84 3.05 25.14 3.84 20.92 4.64
HW (mg) 99.16 11.06 116.17 23.94 106.45 25.95
HW/BW (mg/g) 4.57 0.41 4.63 0.50 5.15 1.01
LVD diastole (mm) 4.16 0.18 4.13 0.52 3.99 0.45
LVD systole (mm) 3.09 0.23 3.06 0.29 2.99 0.41
FS (%) 25.64 4.46 26.24 2.32 25.12 4.57
EF (%) 50.92 7.61 51.12 4.71 48.96 6.71
a BW, body weight; HW, heart weight; LVD, left ventricular diameter; FS, fractional
shortening; EF, ejection fraction.
TABLE 1 Body composition analysis of transgenic and ncKO animals
Characteristic
Value for mouse type:
WT (n 6) TG (n 6) ncKO (n 6)
Wt (g) 23.00 4.22 24.07 4.79 20.93 4.72
Fat (%) 15.19 1.08 14.43 1.01 16.95 3.41
Free water (%) 6.43 0.42 6.75 0.74 6.67 0.56
Muscle (%) 75.96 1.18 76.51 1.46 74.16 3.97
TABLE 3 ECG of transgenic and ncKO animals
Characteristic
Value for mouse type:
WT (n 6) TG (n 6) ncKO (n 6)
Interval (ms)
PR 39.70 1.14 41.22 1.36 39.49 3.08
QRS 13.26 1.55 11.74 1.65 11.32 1.45
QT 25.66 1.79 26.05 2.14 25.70 0.91
Amplitude (mV)
P 0.08 0.02 0.09 0.02 0.11 0.02
Q 
0.05 0.03 
0.06 0.04 
0.08 0.08
R 1.55 0.34 1.53 0.35 1.60 0.37
S 
0.45 0.15 
0.33 0.27 
0.49 0.26
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chicken CAR were not infected (Fig. 6B). To validate these find-
ings, RNA from transfected cells 4 h postinfectionwas isolated and
analyzed by qRT-PCR. Viral RNA was detected only in cells ex-
pressing mCAR and not in cells expressing chicken or no CAR
(Fig. 6C). Nontransfected CHO cells were CAR negative, and only
the transfected CAR species was expressed in the cells (Fig. 6D
and E).
To relate these functional differences to differences in the
amino acid compositions of chicken versus mouse CAR, we per-
formed sequence alignments and modeled the interaction site of
chicken CAR. As the N-terminal Ig domain is most important for
virus binding as well as the interaction with other IgSF proteins,
and as the structures had been solved for human and mouse, we
focused our analysis on that region (Fig. 7). The published binding
sites of CVB3 to CAR (15) comprise 27 amino acids (aa), of which
24 are identical betweenmouse and human (89%homology). The
differentiating amino acids are located close to the D2 domain of
CAR, suggesting only minor relevance of this region for virus
binding. In contrast, the homology of CVB3 binding amino acids
betweenmouse and chicken is 63% (17 identical aa). Modeling of
the chickenCARD1 domain localizes changed amino acids also to
the upper part of the D1 domain. The published interaction sites
between two CAR molecules (25, 26) are highly conserved be-
tween mouse and human (100%) and mouse and chicken (80%).
The differential amino acids are not clustered but distributed
throughout the D1 domain. These species-specific differences
might explain why chCAR can preserve the cellular function of
CAR but not CVB3 replication.
With the generation of our novel ncKOmouse, we were able to
show that the essential function of CAR in vivo is related to cardiac
development. The species-specific differences in virus uptake ver-
sus cardiac function became apparent as chCAR restored normal
heart development but did not mediate virus infection. This can
be explained by differential conservation of virus binding sites
versus sites involved in cellular interactions.
DISCUSSION
CAR is amultifunctional protein that not onlymediates uptake of
type B coxsackieviruses and adenoviruses but also is required for
critical cellular functions such as cell contact formation and signal
transduction. Thus, CAR-deficient mice die early in embryonic
development (32–34). In this study, we show that the expression
of chicken CAR in the mouse heart is sufficient to rescue the em-
bryonic-lethal CAR KO phenotype as it adopts the physiological
functions of mouse CAR. Surprisingly, it does not restore suscep-
tibility to coxsackievirus infection.
To study the cellular function of CAR, various KO mice have
been generated. The conventional KO of CAR exon 1 or 2 leads to
cardiacmalformations and embryonic lethality between day E11.5
and E13.5. Survival of cardiac tissue-specific knockout mice de-
pends on the promoter driving the Cre transgene and the targeted
exon, ranging from complete lethality in the MHCcre-driven KO
of CAR exon 1 or the TnTcre-drivenKOof CAR exon 2 (33, 36) to
survival of 20% or 100% of the embryos in the MHCcre-driven
CAR exon 2 KO (32–34). The inducible KO of CAR in the adult
heart is compatible with life but results in an electrical phenotype
with impaired cardiac function (35–37). Together, these mouse
models indicate an important role of CAR in development and
function of the heart.
Here, we used a rescue approach to evaluate the role of CAR in
extracardiac tissues and study species-specific differences in virus
uptake versus cardiac physiology. We used the MLC-2 promoter,
whichmimics the physiological timing of CAR expression (32, 49,
52, 53), to express chicken CAR exclusively in the mouse heart.
This approach was associated with a dose-dependent lethality, as
mice expressing high levels of the transgene died within the first
weeks after birth while founders with lower levels of chicken CAR
expression survived. This is consistent with reported observations
after a 6-fold overexpression of CAR in the heart (54). These ani-
mals develop cardiomyopathy and cardiac hypertrophy and die
within their first month of life. In contrast, our surviving trans-
genic mice with low expression of the chCAR transgene and
proper developmental regulation through the MLC-2 promoter
do not show any obvious abnormalities.
The chCAR transgene rescued the embryonic lethality of the
FIG 2 In ncKO mice, noncardiac tissues are protected from CVB3 infection.
CAR WT and ncKO animals were inoculated intraperitoneally with 1  105
PFU of the CVB3Nancy strain and analyzed after 10 days byH&E staining and
in situ hybridization on paraffin sections. (A) H&E staining reveals necrosis
and inflammation with infiltration of mononuclear cells in WT pancreas,
which is not detected in the ncKO animals. The morphology of spleen, liver,
kidney, and lung was normal. There was no sign of infection in any ncKO
tissue analyzed. (B) CVB3 infection was documented by the presence of viral
RNA in WT pancreas. There was no viral RNA as a sign of replicating virus in
ncKO animals. WT, n 10; ncKO, n 10. Bar, 50 m.
Freiberg et al.
7350 jvi.asm.org Journal of Virology
 o
n
 M
arch 6, 2017 by UNIVERSITEITSBIBLIO
THEEK
http://jvi.asm.org/
D
ow
nloaded from
 
homozygous CAR KOmice, resulting in normal cardiac function
and development of the ncKO animals (32–34). Thus, expression
of CAR exclusively in the heart is sufficient for the survival of CAR
KO embryos.
Postnatal development of the ncKOmice was normal, includ-
ing body weight, body composition, heart weight, and cardiac
morphology. The spectrum of cardiac pathology in CARKOmice
ranges from enlarged mitochondria over thin myofilament bun-
dles (34) to disrupted connections of the myofilaments to the
intercalated discs (35). In contrast, there were no obvious mor-
phological, ultrastructural, or functional changes in our ncKO
animals, including mechanics and electrical activity, as deter-
mined by echocardiography and ECG. The electrical conduction
defect with severe AVblock, the hallmark of the adult CAR knock-
FIG3 The immune response toCVB3 is not induced in ncKOmice. SerumofCVB3-inoculatedWTandncKOanimalswas collected 4 and 10 days after infection
(dpi). (A) Specific antibody production was determined using a CVB3 serum ELISA. At 4 dpi, CVB3-specific IgGs are present in WT animals and increase
through day 10 postinfection. No CVB3-specific antibodies were detected in ncKO animals. (B) In the acute phase of infection, the inflammation marker
RANTES was upregulated more than 5-fold in the serum of WT but not ncKO animals. At 10 dpi, serum levels of RANTES are decreased in WT mice but still
elevated compared to those in ncKO mice. *, P 0.05; ***, P 0.005. Uninfected: WT, n 3; ncKO, n 6; 4 dpi: WT, n 4; ncKO, n 3; 10 dpi: WT, n
6; ncKO, n 8.
FIG 4 Replacing mouse with chicken CAR prevents CVB3 entry and the associated cardiac pathology. Analysis of virus uptake and the associated immune
response in hearts expressing mouse versus chicken CAR (CARWT and ncKO animals). (A to D) H&E staining documents the infiltration with mononuclear
cells (A) and replicating virus detected by in situ hybridization of wild-type but not ncKOhearts 10 days (B) after intraperitoneal infectionwith CVB3. Viral RNA
detected by qRT-PCR (C) as well as the viral capsid protein VP1 (D) was present only in the hearts of WT but not ncKO mice at 4 dpi. (E) The inflammation
markers RANTES, TNF-	, IFN-1, IL-6, and IL-10 were induced only in the hearts ofWT and not ncKO animals as determined by TaqMan analysis. *, P 0.05;
**, P 0.01; ***, P 0.001. WT, n 4; ncKO, n 3. Bars, 50 m.
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out heart (35, 36), was completely restoredwith the chicken trans-
gene. Indeed, normal cardiac development and function in the
ncKO mouse indicate that chCAR can replace the physiological
function of the endogenous CAR in the mouse heart.
The survival of the ncKO mouse suggests that CAR is not a
critical component in the development of extracardiac tissues.
The phenotype of the tamoxifen-inducible ubiquitous CAR
knockout (55) with tamoxifen injection at E12.5 resulted in death
on day E18.5. The embryos suffered from subcutaneous edema
and hemorrhages, and the presence of erythrocytes in lymphatic
vessels had been attributed to a potential contribution of CAR to
the separation between blood and lymphatic vessels (55). Our
analysis of the ncKOmouse, which did not reproduce this pheno-
type, would suggest that the hemorrhage is more likely secondary
to the cardiac phenotype and not a vascular defect.
The expression of CAR in male germ cells and Sertoli cells
suggests a function for CAR in male fertility (56, 57). As our ani-
mals breed and produce normal litters, an essential function in
male fertility can be excluded. These findings are consistent with
the inducible ubiquitous downregulation of CAR in adult mice
that has no effect on metabolism, fertility, or behavior (37). The
localization of CAR to tight junctions implies a role for CAR in
epithelial barrier function and tissue homeostasis (58). Accord-
ingly, we investigated the blood-brain barrier in ncKO mice and
did not find an increased permeability, indicating an intact barrier
function. The lack of an obvious extracardiac phenotype in the
ncKOmouse under baseline conditions does not exclude a role for
CAR in noncardiac tissues, and we anticipate that future appro-
priate challengeswill help develop the ncCARKOas a suitable tool
to study the role of CAR in the lung endothelium or kidney or in
themigration of neutrophils (59). Conveniently, the robust rescue
avoids the necessity to induceCARdeficiency and provides a com-
plete loss of CAR in all cells from early embryonic development.
Challenging wild-type mice with CVB3 resulted in infection,
virus replication, and the expected pathology, predominantly in
heart and pancreas as the prime target tissues (3, 4). The ncKO
mouse was protected from virus-induced pathology. Unexpect-
edly, this involved not only noncardiac tissues but also the heart,
which did not show any signs of infection despite the cardiac ex-
pression of chCAR. In hearts of infected rescue animals, we did
not detect viral RNA by in situ hybridization or TaqMan analysis,
nor did we detect CVB3 capsid protein VP1. There were no signs
of histopathology and no induction of an immune response in
infected ncKO animals. A similar protection of the pancreas or
heart has been reported in the respective tissue-specific CAR KO
mice with reduced virus load, inflammation, and tissue damage
compared to those of WT mice (3, 4). The absence of viral repli-
cation in heart or pancreas as primary organs of CVB3 replication
was not associated with reduced virus spread or replication in
other organs (3, 4).
To exclude a compartmentalization effect where the loss of
CAR in noncardiac tissue prevents virus spread, we monitored
FIG5 Protection fromCVB3-associated pathology is independent of the delivery route. CARWTand ncKO animals were inoculated intravenously with 1 106
PFU of the CVB3 Nancy strain. (A) At 10 dpi, viral RNA was present in heart and pancreas of WT but not ncKO animals as detected by in situ hybridization of
paraffin sections. (B)CVB3-specific antibodies were detected in bothWTandncKOanimals by using a coxsackievirus IgG-specific ELISA. The immune response
was significantly reduced in ncKO animals. (C) Serum levels of RANTES at 10 dpi were increased only in WT animals. *, P 0.05; ***, P 0.001. WT, n 4;
ncKO, n 5. Bar, 50 m.
FIG 6 Species-specific variation in CAR affects CVB3 infection. CAR-negative CHO cells were transfected with CAR from mouse (mCAR) and chicken
(chCAR), infected with CVB3, and analyzed using a plaque assay. (A) The CVB3 Nancy strain does not replicate in CAR-negative CHO cells, whereas the CVB3
PD strain infects cells independently ofCAR. (B)Replicating virus arose only fromcells transfectedwithmCAR.UntransfectedCHOcells or cells transfectedwith
chCAR did not contain virus. (C) At 4 h postinfection, CVB3 RNA was present only in mCAR-transfected cells and not in those expressing chCAR. (D and E)
TaqMan analysis confirmed the species-specific CAR expression. *, P 0.05; ***, P 0.001.
Freiberg et al.
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cardiac infection after intravenous versus intraperitoneal delivery
of CVB3. Neither route of virus administration resulted in cardiac
damage or viral replication. After intravenous application, we de-
tected CVB3-specific antibodies in the serum of infected rescue
animals, although at lower levels than those inwild-typemice. The
production of antibodies likely results from circulating virus in
the blood and not from the infection, as the induction of an im-
mune response by nonreplicating virus capsids has previously
been described (60).
With mounting evidence that chCAR does not mediate virus
entry in vivo, we used a cell culture-based system to eliminate the
complicating effects of virus spread and immune response. In
CAR-negative CHO cells transfected withmouse or chicken CAR,
we compared virus replication levels via plaque assays and found
FIG 7 Cellular and viral CAR binding sites differ between species. Sequence analysis and modeling of the N-terminal Ig domain of human, mouse, and chicken
CAR. Published binding sites of the CAR-CVB3 interaction or CAR-CAR are displayed on a dark gray background. Homology to the published sites is indicated
by the light gray background. (A) Alignment of the first D1 domain shows the conservation of amino acids within the binding sites for CVB3 between Homo
sapiens, Mus musculus, and G. gallus. Three amino acids are exchanged between human and mouse, and 7 additional amino acids are exchanged in chicken
(indicated in red). An asterisk indicates a position with a single, fully conserved residue. A colon indicates conservation between groups of strongly similar
properties. A period indicates conservation between groups of weakly similar properties. (B) The structures of the human and mouse Ig domains have been
solved, and the G. gallus D1 domain was modeled by using human D1 domain as a template. Nonconserved amino acids are indicated in red. The additional
amino acid exchanges in G. gallusmainly affect the upper part of the molecule. (C) The mutations affecting amino acids in the chicken Ig domain (red) do not
cluster within the structure. (D) The amino acids involved inCARdimerization (blue) arewell conserved between species, with complete identity betweenmouse
and human and 4 additional mutations in chicken.
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that unlikemouse CAR, chCARdoes notmediate CVB3 infection.
CVB3 has been reported to infect several species, including hu-
mans and other primates (5–7) and mice and dogs (8, 9). Infec-
tions of nonmammalian species have not been reported, but
transfection of CAR-negative CHO cells with zebrafish CAR al-
lows CVB3 infection (61). Chicken CAR did not mediate virus
uptake into CHO cells, possibly related to the diversity of amino
acid sequences, with a homology between zebrafish and chicken
CAR of only 51%. While amino acid conservation of CAR is high
between mammals, there is a considerable disparity with non-
mammalian species, specifically between sites involved in cellular
versus virus-host interactions. Specifically, the CVB3 binding sites
are highly conserved between human andmouse but not between
human and chicken. Modeling of the protein structure localizes
the 10 nonconserved amino acids between human and chicken
throughout the D1 region. In contrast, the 3 aa differentiating
human andmouse localize in D1 close to the D2 domain, which is
not as accessible for interactions as is the distal region of the mol-
ecule. Amino acids of the N-terminal Ig domain that are involved
in the physiological interaction between CAR molecules or CAR
and other members of the IgSF and the cytoplasmic tail with its
PDZ consensus site (GSIV) are conserved between human,
mouse, and chicken (15). This suggests that amino acids involved
in CAR’s physiological interactions underlie a higher selection
pressure and are conserved between species, in contrast to amino
acids that relate to the interaction with pathogens. Thus, CAR-
dependent cell contacts and signaling pathways can be sustained
by chCAR, but CVB3 infection cannot.
In summary, expression of chCAR in the heart of CAR knock-
out mice has allowed us to rescue the embryonic-lethal KO phe-
notype and address interspecies differences in virus-host interac-
tions. Replacing mouse with chicken CAR protects animals from
CVB3 infection but maintains normal cardiomyocyte morphol-
ogy and function. Thus, the cardiac rescue survives and does not
display any obvious noncardiac phenotypes. Accordingly, we ex-
pect only minor nonmuscle side effects from CAR-directed ther-
apeutic strategies and added safety for cardiac antiviral strategies
that exploit species-specific differences in CAR physiology versus
pathology.
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